Developer docs
API playgroundTry for free, no card

Search company profiles

Home Biosciences

Full company profile

uuid0002nvw

Namestring
Home Biosciences
Legal namestring
Home Biosciences SAS
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Home Biosciences was a Paris-based biotech venture builder founded in 2020 by David Schilansky and Magali Richard, positioned as the first dedicated biotech venture builder in Continental Europe. It operated an asset-centric, hub-and-spoke model — identifying academic science, assembling dedicated project teams, providing operational support and seed funding, and growing standalone biotech companies toward independent commercialization. Over five years it created three portfolio companies: One Biosciences SAS (single-cell AI-driven molecular profiling for advanced cancer care, co-founded with Institut Curie and Céline Vallot), Sequantrix GmbH (fibrotic disease drug discovery leveraging one of the world's largest human multi-modal single-cell datasets, co-founded with researchers from RWTH Aachen), and Apikal Therapeutics SAS (co-founded with Necker Hospital's Guillaume Canaud and CNRS's Laurent Micouin). The firm raised a single $15 million Seed round in November 2021, co-led by Redmile Group and Sofinnova Partners, with no subsequent funding rounds disclosed.

The underlying technology stack spans proprietary single-cell wet-lab and computational pipelines (One Biosciences) and a large multi-modal single-cell fibrosis dataset (Sequantrix). The business model was equity-value creation through venture portfolio ownership rather than product revenue or licensing royalties at the parent level; the parent did not sell products or services directly. In January 2025, Home Biosciences ended day-to-day operations and transitioned to dormant, non-operating status with no Board of Directors, refocusing exclusively on supporting the three portfolio companies it had co-founded.

Short descriptiontext

Home Biosciences was a Paris-based biotech venture builder creating portfolio companies (One Biosciences, Sequantrix, Apikal Therapeutics) via a hub-and-spoke model. Founded in 2020 with $15M from Redmile Group and Sofinnova Partners, it became dormant in January 2025.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech venture building, biotech company creation, asset-centric biotech, drug discovery ventures, hub-and-spoke biotech
Industry2 codes
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAGAGAE
Process Development & Tech Transfer (Upstream/Downstream/MSAT)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotech Venture Building
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Equity value creation through venture portfolio
TypeLicensing Royalties
Description

Home Biosciences generates value through equity ownership in the companies it co-founds and builds. As a venture builder, the company creates new biotech companies from scratch and builds value through their development, likely through equity appreciation and eventual exits.

homebiosciences.com
2Operational support and funding
TypeManaged Services
Description

Provides funding and operational support to portfolio companies, creating value through successful company development and scale-up.

homebiosciences.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Home Biosciences was a European biotech venture builder that identified promising academic science, co-founded dedicated biotech companies, and provided them with funding, operational support, and dedicated project teams under a hub-and-spoke operating model. In five years it built three companies from scratch: One Biosciences (single-cell and AI-based molecular profiling for cancer care), Sequantrix (fibrotic disease drug discovery using a large multi-modal single-cell dataset), and Apikal Therapeutics (therapeutics co-founded with academic partners). The company ended day-to-day operations in January 2025 and transitioned to non-operating/dormant status.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Built three companies from scratch in five years
+1 more record
Product overview1 text field

Home Biosciences was the first and leading biotech company focused on venture building in Continental Europe, operating as a hub-and-spoke model. The company functioned as a venture builder that created and scaled biotech companies from scratch. It operated from 2020 until January 2025 when it ended day-to-day operations and moved to non-operating mode, now focusing on building value for its portfolio companies. The three venture companies it created are: One Biosciences (molecular profiling/cancer care using single-cell and AI technology), Sequantrix (fibrotic disease drug discovery using multi-modal single-cell datasets), and Apikal Therapeutics (co-founded with academic partners from Necker Hospital and CNRS).

Product and service3 records
1One Biosciences
CategoryVenture Company / Techbio (molecular profiling for cancer care)
Description

One Biosciences is a Techbio company in the molecular profiling space that uses single-cell-based proprietary technology, including AI-driven analysis applied to clinical specimens, to create a functional profile of a given patient's tumor at a given point in time, with potential to deconvolute complex biology in advanced cancer.

2Sequantrix
CategoryVenture Company / Drug discovery (fibrotic diseases)
Description

Sequantrix leverages one of the world's largest human multi-modal, single-cell datasets in fibrotic diseases to discover and validate novel targets and develop anti-fibrotic drug candidates up to clinical proof of concept, regrouping leading pioneers in fibrosis research, clinical care and computational science.

3Apikal Therapeutics
CategoryVenture Company / Therapeutics development
Description

Apikal Therapeutics is a venture company co-founded by Home Biosciences with Guillaume Canaud (Necker Hospital) and Laurent Micouin (CNRS), focused on developing innovative therapeutic approaches.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founding partner for One Biosciences alongside Céline Vallot. Institut Curie is a leading French cancer research institute providing scientific expertise and research capabilities.

2Céline Vallot
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founder of One Biosciences with Home Biosciences and Institut Curie. Scientist bringing expertise in molecular profiling and cancer research.

homebiosciences.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founder of Sequantrix. MD, PhD, bringing clinical and scientific expertise in fibrosis research.

4Rebekka K. Schneider
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founder of Sequantrix. MD, PhD, contributing expertise in fibrosis research and clinical care.

homebiosciences.com
5Michael Rheinnecker
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CEO of Sequantrix. Brings executive leadership and operational expertise to the venture.

homebiosciences.com
6Guillaume Canaud
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founder of Apikal Therapeutics. Physician at Necker Hospital bringing clinical expertise and medical insight.

homebiosciences.com
7Laurent Micouin
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founder of Apikal Therapeutics. Researcher at CNRS (French National Centre for Scientific Research) providing scientific foundation.

homebiosciences.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic medical institution affiliated with Guillaume Canaud for Apikal Therapeutics co-founding.

9CNRS (French National Centre for Scientific Research)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Premier French research institution affiliated with Laurent Micouin for Apikal Therapeutics co-founding.

homebiosciences.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Roivant is an asset-centric biotech holding company that launches and operates multiple subsidiary biotechs (Vants), directly mirroring Home Biosciences' hub-and-spoke venture builder model in the biotech space.

TypeDirect peer
Description

PureTech is a clinical-stage biotech company that founded and develops multiple therapeutic programs from internal R&D, functioning as a European/UK biotech venture builder and incubator similar to Home Biosciences.

TypeDirect peer
Description

Medicxi is a European biotech-focused venture capital firm that incubates and builds single-asset or asset-centric biotech companies, sharing Home Biosciences' model of creating dedicated biotech vehicles around specific scientific programs.

TypeDirect peer
Description

Apollo Therapeutics is a UK-based biotech venture builder formed by AstraZeneca, GSK, J&J and others to translate academic research into new biotech companies, directly comparable to Home Biosciences' academic-partnered venture creation model.

TypeBroad incumbent
Description

Flagship Pioneering is the largest and most established biotech venture builder, having created companies like Moderna. It pioneered the asset-centric creation model that inspired Home Biosciences, though at much larger scale.

TypeBroad incumbent
Description

BridgeBio uses an asset-centric model to develop multiple therapeutic programs for genetic diseases. While broader and more clinically advanced than Home Biosciences, it shares the hub-and-spoke philosophy of focused, dedicated teams per program.

TypeDirect peer
Description

Arix Bioscience was a London-listed biotech venture builder focused on creating and developing multiple biotech companies, closely paralleling Home Biosciences' model of portfolio-based biotech company creation in Europe.

TypeEmerging player
Description

Vesalius is a Flagship-founded biotech company applying a venture builder approach to common disease drug discovery, with comparable academic-partnered, asset-centric philosophy to Home Biosciences.

TypeEmerging player
Description

Newleos Therapeutics is an early-stage biotech venture created by a European team to develop neuroscience therapeutics from academic research, sharing Home Biosciences' model of building single-program biotechs around founder-scientist expertise.

TypeEmerging player
Description

STORM Therapeutics is a UK-based biotech spun out of Cambridge research to develop RNA-modifying enzyme inhibitors, comparable to Home Biosciences' portfolio companies that were built around specific academic discoveries.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Home Biosciences

Biotech Venture Buildinghomebiosciences.com

Home Biosciences was a Paris-based biotech venture builder creating portfolio companies (One Biosciences, Sequantrix, Apikal Therapeutics) via a hub-and-spoke model. Founded in 2020 with $15M from Redmile Group and Sofinnova Partners, it became dormant in January 2025.

What Home Biosciences does

Home Biosciences was a Paris-based biotech venture builder founded in 2020 by David Schilansky and Magali Richard, positioned as the first dedicated biotech venture builder in Continental Europe. It operated an asset-centric, hub-and-spoke model — identifying academic science, assembling dedicated project teams, providing operational support and seed funding, and growing standalone biotech companies toward independent commercialization. Over five years it created three portfolio companies: One Biosciences SAS (single-cell AI-driven molecular profiling for advanced cancer care, co-founded with Institut Curie and Céline Vallot), Sequantrix GmbH (fibrotic disease drug discovery leveraging one of the world's largest human multi-modal single-cell datasets, co-founded with researchers from RWTH Aachen), and Apikal Therapeutics SAS (co-founded with Necker Hospital's Guillaume Canaud and CNRS's Laurent Micouin). The firm raised a single $15 million Seed round in November 2021, co-led by Redmile Group and Sofinnova Partners, with no subsequent funding rounds disclosed.

The underlying technology stack spans proprietary single-cell wet-lab and computational pipelines (One Biosciences) and a large multi-modal single-cell fibrosis dataset (Sequantrix). The business model was equity-value creation through venture portfolio ownership rather than product revenue or licensing royalties at the parent level; the parent did not sell products or services directly. In January 2025, Home Biosciences ended day-to-day operations and transitioned to dormant, non-operating status with no Board of Directors, refocusing exclusively on supporting the three portfolio companies it had co-founded.

Home Biosciences firmographics

Firmographics
Name
Home Biosciences
Legal name
Home Biosciences SAS
Website
https://homebiosciences.com
Company type
Private
Founded year
2020
Operating status
Closed
Headcount range
1–10 employees
Short description
Home Biosciences was a Paris-based biotech venture builder creating portfolio companies (One Biosciences, Sequantrix, Apikal Therapeutics) via a hub-and-spoke model. Founded in 2020 with $15M from Redmile Group and Sofinnova Partners, it became dormant in January 2025.
Ownership category
akta.pro rank

Home Biosciences industry classification

Industry
Product category
Biotech Venture Building
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAGAGAE
Process Development & Tech Transfer (Upstream/Downstream/MSAT)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Biotech venture building
  • Biotech company creation
  • Asset-centric biotech
  • Drug discovery ventures
  • Hub-and-spoke biotech

Where Home Biosciences is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Home Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Equity value creation through venture portfolio: Home Biosciences generates value through equity ownership in the companies it co-founds and builds. As a venture builder, the company creates new biotech companies from scratch and builds value through their development, likely through equity appreciation and eventual exits.
  2. Operational support and funding: Provides funding and operational support to portfolio companies, creating value through successful company development and scale-up.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Home Biosciences product offering

Product offering

Core offering

Home Biosciences was a European biotech venture builder that identified promising academic science, co-founded dedicated biotech companies, and provided them with funding, operational support, and dedicated project teams under a hub-and-spoke operating model. In five years it built three companies from scratch: One Biosciences (single-cell and AI-based molecular profiling for cancer care), Sequantrix (fibrotic disease drug discovery using a large multi-modal single-cell dataset), and Apikal Therapeutics (therapeutics co-founded with academic partners). The company ended day-to-day operations in January 2025 and transitioned to non-operating/dormant status.

Product overview

Home Biosciences was the first and leading biotech company focused on venture building in Continental Europe, operating as a hub-and-spoke model. The company functioned as a venture builder that created and scaled biotech companies from scratch. It operated from 2020 until January 2025 when it ended day-to-day operations and moved to non-operating mode, now focusing on building value for its portfolio companies. The three venture companies it created are: One Biosciences (molecular profiling/cancer care using single-cell and AI technology), Sequantrix (fibrotic disease drug discovery using multi-modal single-cell datasets), and Apikal Therapeutics (co-founded with academic partners from Necker Hospital and CNRS).

Differentiator

Problem solved

Functional benefit

Products and services

  • One Biosciences One Biosciences is a Techbio company in the molecular profiling space that uses single-cell-based proprietary technology, including AI-driven analysis applied to clinical specimens, to create a functional profile of a given patient's tumor at a given point in time, with potential to deconvolute complex biology in advanced cancer.
  • Sequantrix Sequantrix leverages one of the world's largest human multi-modal, single-cell datasets in fibrotic diseases to discover and validate novel targets and develop anti-fibrotic drug candidates up to clinical proof of concept, regrouping leading pioneers in fibrosis research, clinical care and computational science.
  • Apikal Therapeutics Apikal Therapeutics is a venture company co-founded by Home Biosciences with Guillaume Canaud (Necker Hospital) and Laurent Micouin (CNRS), focused on developing innovative therapeutic approaches.

Quantifiable outcome

  • Built three companies from scratch in five years
  • +1 more outcomes

Companies that use Home Biosciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Home Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Home Biosciences partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core.

  • Institut CuriecoreStrategic or Co-development PartnerCo-founding partner for One Biosciences alongside Céline Vallot. Institut Curie is a leading French cancer research institute providing scientific expertise and research capabilities.
  • Céline VallotcoreStrategic or Co-development PartnerCo-founder of One Biosciences with Home Biosciences and Institut Curie. Scientist bringing expertise in molecular profiling and cancer research.
  • Rafael KramanncoreStrategic or Co-development PartnerCo-founder of Sequantrix. MD, PhD, bringing clinical and scientific expertise in fibrosis research.
  • Rebekka K. SchneidercoreStrategic or Co-development PartnerCo-founder of Sequantrix. MD, PhD, contributing expertise in fibrosis research and clinical care.
  • Michael RheinneckercoreStrategic or Co-development PartnerCEO of Sequantrix. Brings executive leadership and operational expertise to the venture.
  • Guillaume CanaudcoreStrategic or Co-development PartnerCo-founder of Apikal Therapeutics. Physician at Necker Hospital bringing clinical expertise and medical insight.
  • Laurent MicouincoreStrategic or Co-development PartnerCo-founder of Apikal Therapeutics. Researcher at CNRS (French National Centre for Scientific Research) providing scientific foundation.
  • Necker HospitalcoreStrategic or Co-development PartnerAcademic medical institution affiliated with Guillaume Canaud for Apikal Therapeutics co-founding.
  • CNRS (French National Centre for Scientific Research)coreStrategic or Co-development PartnerPremier French research institution affiliated with Laurent Micouin for Apikal Therapeutics co-founding.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Home Biosciences competitors and assessment

Company assessment

Direct peers

  • Roivant Sciences: Roivant is an asset-centric biotech holding company that launches and operates multiple subsidiary biotechs (Vants), directly mirroring Home Biosciences' hub-and-spoke venture builder model in the biotech space.
  • PureTech Health: PureTech is a clinical-stage biotech company that founded and develops multiple therapeutic programs from internal R&D, functioning as a European/UK biotech venture builder and incubator similar to Home Biosciences.
  • Medicxi: Medicxi is a European biotech-focused venture capital firm that incubates and builds single-asset or asset-centric biotech companies, sharing Home Biosciences' model of creating dedicated biotech vehicles around specific scientific programs.
  • Apollo Therapeutics: Apollo Therapeutics is a UK-based biotech venture builder formed by AstraZeneca, GSK, J&J and others to translate academic research into new biotech companies, directly comparable to Home Biosciences' academic-partnered venture creation model.
  • Arix Bioscience (now ITC Therapeutics): Arix Bioscience was a London-listed biotech venture builder focused on creating and developing multiple biotech companies, closely paralleling Home Biosciences' model of portfolio-based biotech company creation in Europe.

Broad incumbents

  • Flagship Pioneering: Flagship Pioneering is the largest and most established biotech venture builder, having created companies like Moderna. It pioneered the asset-centric creation model that inspired Home Biosciences, though at much larger scale.
  • BridgeBio Pharma: BridgeBio uses an asset-centric model to develop multiple therapeutic programs for genetic diseases. While broader and more clinically advanced than Home Biosciences, it shares the hub-and-spoke philosophy of focused, dedicated teams per program.

Emerging players

  • Vesalius Therapeutics: Vesalius is a Flagship-founded biotech company applying a venture builder approach to common disease drug discovery, with comparable academic-partnered, asset-centric philosophy to Home Biosciences.
  • Newleos Therapeutics: Newleos Therapeutics is an early-stage biotech venture created by a European team to develop neuroscience therapeutics from academic research, sharing Home Biosciences' model of building single-program biotechs around founder-scientist expertise.
  • STORM Therapeutics: STORM Therapeutics is a UK-based biotech spun out of Cambridge research to develop RNA-modifying enzyme inhibitors, comparable to Home Biosciences' portfolio companies that were built around specific academic discoveries.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Home Biosciences social profiles

Digital presence

Home Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Home Biosciences leadership team

Management profile

Number of profiles

Profiles3 records

Home Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Home Biosciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Home Biosciences M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Home Biosciences

What does Home Biosciences do?

Home Biosciences was a European biotech venture builder that identified promising academic science, co-founded dedicated biotech companies, and provided them with funding, operational support, and dedicated project teams under a hub-and-spoke operating model. In five years it built three companies from scratch: One Biosciences (single-cell and AI-based molecular profiling for cancer care), Sequantrix (fibrotic disease drug discovery using a large multi-modal single-cell dataset), and Apikal Therapeutics (therapeutics co-founded with academic partners). The company ended day-to-day operations in January 2025 and transitioned to non-operating/dormant status.

Is Home Biosciences a public or private company?

Home Biosciences is a private company. It is classified as venture growth investor backed and is currently closed.

When was Home Biosciences founded?

Home Biosciences was founded in 2020. It employs 1 to 10 people.

Where is Home Biosciences based?

Home Biosciences is headquartered in Paris, France, in the Europe region.

How does Home Biosciences make money?

Two revenue lines are on record. Equity value creation through venture portfolio is the primary driver. The others are operational support and funding.

Who are Home Biosciences's main competitors?

Direct peers on record are Roivant Sciences, PureTech Health, Medicxi, Apollo Therapeutics and Arix Bioscience (now ITC Therapeutics). Broad incumbents are Flagship Pioneering and BridgeBio Pharma. Emerging players are Vesalius Therapeutics, Newleos Therapeutics and STORM Therapeutics.

Does Home Biosciences have an API?

No public API is recorded for Home Biosciences.

What industry is Home Biosciences in?

Home Biosciences's product category is Biotech Venture Building. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAGAGAE, Process Development & Tech Transfer (Upstream/Downstream/MSAT). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals